Galectin-3 in Heart Failure: An Update of the Last 3 Years

Carolin Gehlken, Navin Suthahar, Wouter C. Meijers, Rudolf A. de Boer*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

95 Citations (Scopus)

Abstract

Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3–centered diseases.

Original languageEnglish
Pages (from-to)75-92
Number of pages18
JournalHeart Failure Clinics
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Galectin-3 in Heart Failure: An Update of the Last 3 Years'. Together they form a unique fingerprint.

Cite this